Syntara Ltd (SNT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Syntara Ltd (SNT) has a cash flow conversion efficiency ratio of -0.694x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-11.12 Million ≈ $-7.86 Million USD) by net assets (AU$16.02 Million ≈ $11.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Syntara Ltd net asset quality index to measure how much of total assets are equity-financed.
Syntara Ltd - Cash Flow Conversion Efficiency Trend (2004–2023)
This chart illustrates how Syntara Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Syntara Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Syntara Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syntara Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raval ACS Ltd
TA:RVL
|
0.042x |
|
Ferroamp Elektronik AB
ST:FERRO
|
-0.003x |
|
Century Casinos Inc
NASDAQ:CNTY
|
0.052x |
|
Wellbiotec Co. Ltd.
KO:010600
|
-0.033x |
|
MUI Properties Bhd
KLSE:3913
|
0.757x |
|
Pre-Built Public Company Limited
BK:PREB
|
0.106x |
|
CMR S.A.B. de C.V
MX:CMRB
|
0.393x |
|
Plus500 Ltd
LSE:PLUS
|
0.226x |
Annual Cash Flow Conversion Efficiency for Syntara Ltd (2004–2023)
The table below shows the annual cash flow conversion efficiency of Syntara Ltd from 2004 to 2023. For the full company profile with market capitalisation and key ratios, see Syntara Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | AU$9.56 Million ≈ $6.76 Million |
AU$-7.28 Million ≈ $-5.15 Million |
-0.761x | +49.55% |
| 2022-06-30 | AU$10.80 Million ≈ $7.64 Million |
AU$-16.30 Million ≈ $-11.54 Million |
-1.509x | -239.75% |
| 2021-06-30 | AU$2.85 Million ≈ $2.01 Million |
AU$3.07 Million ≈ $2.17 Million |
1.080x | +111.63% |
| 2020-06-30 | AU$1.43 Million ≈ $1.01 Million |
AU$-13.28 Million ≈ $-9.40 Million |
-9.283x | -594.61% |
| 2019-06-30 | AU$14.81 Million ≈ $10.48 Million |
AU$-19.80 Million ≈ $-14.01 Million |
-1.336x | -221.73% |
| 2018-06-30 | AU$11.12 Million ≈ $7.87 Million |
AU$12.21 Million ≈ $8.64 Million |
1.098x | +125.33% |
| 2017-06-30 | AU$3.52 Million ≈ $2.49 Million |
AU$-15.26 Million ≈ $-10.80 Million |
-4.335x | -656.57% |
| 2016-06-30 | AU$20.93 Million ≈ $14.81 Million |
AU$-11.99 Million ≈ $-8.48 Million |
-0.573x | -195.54% |
| 2015-06-30 | AU$36.32 Million ≈ $25.70 Million |
AU$21.78 Million ≈ $15.41 Million |
0.600x | +138.51% |
| 2014-06-30 | AU$18.07 Million ≈ $12.78 Million |
AU$-28.13 Million ≈ $-19.91 Million |
-1.557x | -198.78% |
| 2013-06-30 | AU$67.89 Million ≈ $48.04 Million |
AU$-35.38 Million ≈ $-25.04 Million |
-0.521x | -50.03% |
| 2012-06-30 | AU$109.80 Million ≈ $77.69 Million |
AU$-38.14 Million ≈ $-26.99 Million |
-0.347x | +34.15% |
| 2011-06-30 | AU$70.83 Million ≈ $50.12 Million |
AU$-37.37 Million ≈ $-26.44 Million |
-0.528x | -52.90% |
| 2010-06-30 | AU$115.02 Million ≈ $81.38 Million |
AU$-39.68 Million ≈ $-28.08 Million |
-0.345x | -79.48% |
| 2009-06-30 | AU$137.69 Million ≈ $97.43 Million |
AU$-26.47 Million ≈ $-18.73 Million |
-0.192x | -21.48% |
| 2008-06-30 | AU$119.12 Million ≈ $84.29 Million |
AU$-18.85 Million ≈ $-13.34 Million |
-0.158x | +41.47% |
| 2007-06-30 | AU$76.56 Million ≈ $54.17 Million |
AU$-20.70 Million ≈ $-14.64 Million |
-0.270x | -94.07% |
| 2006-06-30 | AU$98.89 Million ≈ $69.97 Million |
AU$-13.78 Million ≈ $-9.75 Million |
-0.139x | +46.58% |
| 2005-06-30 | AU$35.57 Million ≈ $25.17 Million |
AU$-9.27 Million ≈ $-6.56 Million |
-0.261x | -50.10% |
| 2004-06-30 | AU$26.78 Million ≈ $18.95 Million |
AU$-4.65 Million ≈ $-3.29 Million |
-0.174x | -- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more